Actividad documentación.

https://doi.org/10.1001/jama.2022.2832
Texto original
Sotrovimab is an Fc-engineered human monoclonal antibody that contains the LS
modification to enhance half-life and respiratory mucosal delivery 1, 2. In contrast to
other monoclonal antibodies 3 , sotrovimab targets a highly conserved epitope in the
SARS-CoV-2 spike protein at a region that does not compete with binding of the
angiotensin-converting enzyme 2 4 5. In addition to neutralizing SARS-CoV-2,
sotrovimab has demonstrated effector functions in vitro that may contribute to immune-
mediated viral clearance. Data also suggest that sotrovimab may prevent cell-cell
fusion (ie, syncytia formation) unlike other antibodies that target the receptor-binding
domain.

Bibliografía original (Nature )

1. Pinto, D. et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.

Nature 583, 290–295 (2020).

2. Gaudinski, M. R. et al. Safety and pharmacokinetics of the Fc-modified HIV-1 human

monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults. PLoS Med
15, e1002493 (2018).

3. Focosi, D. & Maggi, F. Neutralising antibody escape of SARS‐CoV‐2 spike protein: Risk
assessment for antibody‐based Covid‐19 therapeutics and vaccines. Rev Med Virol 31, (2021).

4. Starr, T. N., Greaney, A. J., Dingens, A. S. & Bloom, J. D. Complete map of SARS-CoV-2 RBD
mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016.
Cell Rep Med 2, 100255 (2021).

5. Liu, H. et al. 501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to bamlanivimab in
vitro. MAbs 13, (2021).

Texto alternativo
 Sotrovimab is an Fc-engineered human monoclonal antibody that contains the LS
modification to enhance half-life and respiratory mucosal delivery (Pinto et al., 2020) ,
(Gaudinski et al., 2018) . In contrast to other monoclonal antibodies (Focosi & Maggi,
2021), sotrovimab targets a highly conserved epitope in the SARS-CoV-2 spike protein
at a region that does not compete with binding of the angiotensin-converting enzyme 2
(Liu et al., 2021), (Starr et al., 2021). In addition to neutralizing SARS-CoV-2,
sotrovimab has demonstrated effector functions in vitro that may contribute to immune-
mediated viral clearance. Data also suggest that sotrovimab may prevent cell-cell
fusion (ie, syncytia formation) unlike other antibodies that target the receptor-binding
domain.

Bibliografía alternativa (APA)

Focosi, D., & Maggi, F. (2021). Neutralising antibody escape of SARS‐CoV‐2 spike protein: Risk
assessment for antibody‐based Covid‐19 therapeutics and vaccines. Reviews in Medical
Virology, 31(6). https://doi.org/10.1002/rmv.2231

Gaudinski, M. R., Coates, E. E., Houser, K. v., Chen, G. L., Yamshchikov, G., Saunders, J. G., Holman, L.
A., Gordon, I., Plummer, S., Hendel, C. S., Conan-Cibotti, M., Lorenzo, M. G., Sitar, S., Carlton,
K., Laurencot, C., Bailer, R. T., Narpala, S., McDermott, A. B., Namboodiri, A. M., … Ledgerwood,
J. E. (2018). Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal
antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults. PLOS Medicine, 15(1),
e1002493. https://doi.org/10.1371/journal.pmed.1002493

Liu, H., Wei, P., Zhang, Q., Chen, Z., Aviszus, K., Downing, W., Peterson, S., Reynoso, L., Downey, G.
P., Frankel, S. K., Kappler, J., Marrack, P., & Zhang, G. (2021). 501Y.V2 and 501Y.V3 variants of
SARS-CoV-2 lose binding to bamlanivimab in vitro. MAbs, 13(1).
https://doi.org/10.1080/19420862.2021.1919285

Pinto, D., Park, Y.-J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K.,
Zatta, F., de Marco, A., Peter, A., Guarino, B., Spreafico, R., Cameroni, E., Case, J. B., Chen, R. E.,
Havenar-Daughton, C., Snell, G., Telenti, A., … Corti, D. (2020). Cross-neutralization of SARS-
CoV-2 by a human monoclonal SARS-CoV antibody. Nature, 583(7815), 290–295.
https://doi.org/10.1038/s41586-020-2349-y

Starr, T. N., Greaney, A. J., Dingens, A. S., & Bloom, J. D. (2021). Complete map of SARS-CoV-2
RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-
CoV016. Cell Reports Medicine, 2(4), 100255. https://doi.org/10.1016/j.xcrm.2021.100255